Project Grant HT94252310358

Summary The National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) awarded a $683,970 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) beginning April 1, 2026, with completion targeted for March 31, 2031. This award supports research aimed at modifying the pancreatic cancer tumor microenvironment through the αvβ5 integrin pathway. The research focuses on developing and evaluating the IRGD tumor-penetrating peptide as a...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This five-year research initiative focuses on developing and evaluating radiation-guided antibody-drug conjugates (ADCs) as an innovative treatment approach for non-small cell lung cancer (NSCLC). The research leverages a breakthrough discovery of radiation-inducible antigens,...

Federal Grant Award Summary Alelopharma Inc. received a $399,153 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded July 9, 2025, with completion targeted for June 30, 2027. The company will develop an ultra-precision liquid biopsy diagnostic platform capable of detecting anaplastic lymphoma kinase (ALK) gene fusion translocations in cell-free RNA from blood plasma of non-small cell lung cancer (NSCLC) patients....

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $615,399 Project Grant to the University of California, Davis under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025, through July 31, 2030. The award supports the development of a transformable nanoparticle (TNP) platform designed to deliver therapeutic peptides and proteins directly to tumor microenvironments on-demand. The TNP technology transforms from nanoparticles to nanofibrils...

This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at Yale University to investigate the role of the enzyme TENT2 in regulating microRNA-1 (miR-1) degradation in tumor endothelial cells (TECs) and its impact on tumor angiogenesis and progression in non-small cell lung cancer (NSCLC). The $430,684 award, which runs from July 2024 to June 2026, will support two specific aims: 1) determining the role of TENT2 in...

This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...

Federal Grant Award Summary The National Cancer Institute awarded a $682,140 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) on June 4, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop the SPIDER (Synthetic Potentiated Immunogenic Depot Engaged by Radiation) platform for treating locally advanced non-small cell lung cancer. This five-year project, scheduled for completion by May 31, 2031, addresses a critical unmet...

The Leland Stanford Junior University (Stanford University) has been awarded a $462,860 Project Grant from the National Cancer Institute (NCI), an institute of the U.S. Department of Health and Human Services, under the NCI's Cancer Treatment Research program (CFDA 93.395). This 5-year grant supports the development of novel targeted radionuclide therapy (TRT) approaches for the treatment of triple-negative breast cancer (TNBC). The key objectives of this project are to develop MUC1-targeted...

Federal Project Grant Award Summary The National Cancer Institute awarded Velorum Therapeutics Inc. $772,293 on June 3, 2025, under the Cancer Treatment Research program (CFDA 93.395) to advance development of VEL-03, a novel heme-sequestering protein therapeutic targeting non-small cell lung cancer (NSCLC) and other solid tumors. The project, which runs through May 31, 2027, supports a direct-to-Phase II development pathway that includes three primary deliverables: (1) evaluation of VEL-03's...